局部晚期宫颈癌幸存者规律使用阴道扩张器和/或性活动与阴道病变的关联:EMBRACE-I 研究报告
该研究基于前瞻性多中心 EMBRACE-I 研究,评估局部晚期宫颈癌根治性放化疗及图像引导自适应近距离治疗后,规律阴道扩张(使用扩张器和/或性活动)与阴道病变的关系。882 例可评估患者中 565 例(64%)报告规律扩张,中位随访 60 个月。规律扩张与 5 年阴道狭窄 G≥2 风险显著降低相关(23% vs 37%,P≤.001),多因素分析确认(HR 0.630,P=.001);同时与阴道干燥 G≥1(72% vs 67%,P=.028)和出血 G≥1(61% vs 34%,P≤.001)风险显著升高相关。
要点
- 规律阴道扩张(使用扩张器和/或性活动)与阴道狭窄 G≥2 风险显著降低相关(5年23% vs 37%)。
- 规律扩张与阴道干燥 G≥1 及出血 G≥1 风险显著升高相关,但无 G≥2 风险升高。
- 该关联在多因素分析中确认,调整其他危险因素后 HR 0.630(P=.001)。
核心结论
- 规律阴道扩张(定义为使用扩张器和/或性活动)与局部晚期宫颈癌幸存者 G≥2 阴道狭窄风险显著降低相关,提示可能改善阴道通畅性。
- 规律扩张也与轻度 G≥1 阴道干燥和出血风险显著升高相关(无 G≥2 风险升高),这些症状临床上可管理。
研究设计与样本
- 前瞻性、多中心 EMBRACE-I 研究,纳入 2008 至 2015 年间 1416 例局部晚期宫颈癌患者,本报告评估其中 882 例,中位随访 60 个月。
- 医生评估阴道病变(NCI CTCAE v3.0)、阴道扩张器使用及患者报告性活动(EORTC-CX24)在基线和定期随访中前瞻性评估。
- 阴道扩张频率分析在至少 3 次随访的患者亚组中进行。
主要发现
- 882 例可评估患者中 565 例(64%)报告规律扩张(≥50% 随访中报告),不规律/无扩张为 <50% 随访中报告。
- 规律扩张组 5 年阴道狭窄 G≥2 风险为 23%,不规律/无扩张组为 37%(P≤.001)。
- 多因素分析调整其他危险因素后,规律扩张与阴道狭窄 G≥2 风险降低相关(HR 0.630,P=.001)。
- 规律扩张组阴道干燥 G≥1 风险为 72%,不规律/无扩张组为 67%(P=.028)。
- 规律扩张组阴道出血 G≥1 风险为 61%,不规律/无扩张组为 34%(P≤.001)。
关键数值与推荐
- 规律扩张定义为在 ≥50% 随访中报告使用扩张器和/或性活动,不规律/无扩张定义为在 <50% 随访中报告。
- 阴道狭窄 G≥2 的 5 年累积风险:规律扩张组 23% vs 不规律/无扩张组 37%(P≤.001)。
- 多因素分析中规律扩张对阴道狭窄 G≥2 的 HR 为 0.630(P=.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to provide risk estimations for vaginal morbidity with regard to vaginal dilation (summarizing the use of dilators and/or sexual activity) in patients with locally advanced cervical cancer treated with definitive radiochemotherapy and image guided adaptive brachytherapy within the prospective, multi-institutional EMBRACE-I study. METHODS AND MATERIALS: Physician-assessed vaginal morbidity (National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0), use of vaginal dilators, and patient-reported sexual activity (EORTC-CX24) were prospectively assessed at baseline and during regular follow-ups. Frequency analysis for vaginal dilation was performed in a subcohort of patients with ≥3 follow-ups. Regular dilation was defined if reported in ≥50% of follow-ups, and no/infrequent dilation if reported in <50%. Actuarial estimates were calculated with Kaplan-Meier method; comparisons were evaluated with the log-rank test. Univariate and multivariable Cox proportional hazard regressions were used to evaluate risk factors for vaginal stenosis G≥2. RESULTS: The EMBRACE-I study included a total of 1416 patients (2008-2015); 882 were evaluated in the present report with a median follow-up of 60 months. Of those, 565 (64%) reported regular dilation. This was associated with a significantly lower 5-year risk of vaginal stenosis G≥2 compared with no/infrequent dilation (23% vs 37%, P ≤ .001). This univariate finding was confirmed by multivariable analysis, after adjusting for other risk factors (hazard ratio, 0.630; P = .001). Regular vaginal dilation was also associated with a significantly higher risk for vaginal dryness G≥1 (72% vs 67%, P = .028) and bleeding G≥1 (61% vs 34%, P ≤ .001). CONCLUSIONS: Vaginal stenosis represents irreversible fibrotic changes that can cause pain during gynecologic examination and dyspareunia in locally advanced cervical cancer patients survivors. Regular vaginal dilation (defined as the use of dilators and/or sexual activity) is associated with a significantly lower risk for G≥2 vaginal stenosis, suggesting a potential improvement of vaginal patency. It is also associated with a significantly higher risk for mild G≥1 dryness and bleeding (no higher risk for G≥2), which can be clinically managed.
引用
- Kirchheiner K, Zaharie A, Smet S, et al. Association Between the Regular Use of Vaginal Dilators and/or Sexual Activity and Vaginal Morbidity in Locally Advanced Cervical Cancer Survivors: An EMBRACE-I Study Report. Int J Radiat Oncol Biol Phys. 2024. PMID: 39278418. doi:10.1016/j.ijrobp.2024.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。